Moderna Inc - Company Profile
Powered by 
All the sales intelligence you need on Moderna Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Moderna Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Moderna Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
Moderna Inc (Moderna) is a biotechnology company that focuses on the development of messenger RNA (mRNA) therapeutics and vaccines in the areas of infectious diseases, immuno-oncology, rare diseases, and autoimmune diseases. The company develops and discovers drugs that produce proteins or antibodies inside patient cells. Moderna's products include the COVID-19 vaccine and the Respiratory Syncytial Virus (RSV) vaccine. Its pipeline includes various drug modalities such as respiratory virus vaccines, latent and other virus vaccines, oncology therapeutics, and rare disease therapeutics. The company, through its mRNA therapeutics platform, develops and produces human proteins, antibodies, and novel proteins, which help in preventing, treating, and curing diseases. It operates manufacturing units in Canada, the US, the UK, and Australia. Moderna is headquartered in Cambridge, Massachusetts, in the US.
Headquarters
United States of America
Address
325 Binney Street, Cambridge, Massachusetts, 02142
Website
www.modernatx.com
Telephone
1 617 7146500
No of Employees
4,700
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
MRNA (NASD)
Revenue (2024)
$1.9B
-39.9%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
20.8%
(2024 vs 2023)
Market Cap*
$31.6B
Net Profit Margin (2024)
XYZ
-31.9%
(2024 vs 2023)
* As of and is in US$
Moderna Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Respiratory Syncytial Virus Vaccine | SPIKEVAX |
| COVID-19 Vaccine, mRNA | mNEXSPIKE |
| Pipeline | mRESVIA |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In April, the company secured marketing authorization from the European Commission for mCOMBRIAX (mRNA-1083). |
| 2026 | Contracts/Agreements | In February, the company entered into a memorandum of understanding with the Mexican Government, Laboratorios de Biologicos y Reactivos de Mexico, and Laboratorios Liomont to promote Mexico's health sovereignty and mRNA manufacturing resilience. |
| 2026 | Regulatory Approval | In February, the company received European Commission marketing authorization for its mNEXSPIKE COVID-19 vaccine. |
Competitor Comparison
| Key Parameters | Moderna Inc | Pfizer Inc | Sanofi | BioNTech SE | Novavax Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | France | Germany | United States of America |
| City | Cambridge | New York City | Paris | Mainz | Gaithersburg |
| State/Province | Massachusetts | New York | Ile-de-France | Rheinland-Pfalz | Maryland |
| No. of Employees | 4,700 | 75,000 | 76,493 | 7,807 | 749 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Noubar Afeyan, PhD | Chairman | Executive Board | 2012 | 63 |
| Stephane Bancel | Director; Chief Executive Officer | Executive Board | 2011 | 53 |
| Jamey Mock | Chief Financial Officer | Senior Management | - | 49 |
| Shannon Thyme Klinger | Secretary; Chief Legal Officer | Senior Management | 2021 | 54 |
| Tracey Franklin | Chief People and Digital Technology Officer | Senior Management | 2019 | 46 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer